Zhang Meng,Peng Li,Qiao Zhibin,He Hongtao,Zhou Ye.Rosiglitazone induces cell cycle arrest in hepatocellular carcinoma cell line HepG2 via p38MAPK/p53/p21 pathway[J].J Amry Med Univ (J Third Mil Med Univ),2014,36(03):240-243.
Zhang Meng,Peng Li,Qiao Zhibin,He Hongtao,Zhou Ye.Rosiglitazone induces cell cycle arrest in hepatocellular carcinoma cell line HepG2 via p38MAPK/p53/p21 pathway[J].J Amry Med Univ (J Third Mil Med Univ),2014,36(03):240-243.DOI:
Objective To explore the role of p38MAPK signaling pathway in rosiglitazone (ROZ)-induced cell cycle arrest in human hepatocellular carcinoma cell line HepG2. Methods HepG2 cells were treated with different concentrations of ROZ. The proliferation inhibitory rates were analyzed by MTT assay. Cell cycle distributions were detected by flow cytometry (FCM). Western blotting was used to detect the expression of proteins related to p38MAPK signaling pathway. Results ROZ significantly inhibited proliferation of HepG2 ce
lls
and induced an increase in the percentage of G
0
/G
1
phase cells and a decrease in the percentage of S phase cells accompanied by the change in DNA ploidy (
P
0.05). ROZ increased p38MAPK phosphorylation but not ERK1/2 or JNK phosphorylation
and up-regulated the protein expression levels of p-p53 and p21 in HepG2 cells (
P
0.05). In addition
the ROZ-induced cell proliferation inhibition and cell cycle arrest were partly blocked by p38MAPK inhibitor SB203580
as well as the changes of p-p53 and p21 proteins. Conclusion ROZ inhibits cell proliferation and induces cell cycle arrest in G
0
/G
1
stage of HepG2 cells by the activation of p38MAPK pathway
which may be mediated by the p38MAPK/p53/p21 signaling axis.